TrialJCO precision oncology2022

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.

Philippe L Bedard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.